In the original article, there was a mistake in Figure 5 as published. The symbols (*, **, ***, ns) of statistic differences in Figures 5B–F were wrongly labeled. The wrongly labeled Figure 5 was uploaded by accident when submitting the corrections of proof. The corrected Figure 5 appears below.
FIGURE 5
A combination of SolB and WeD treatment dramatically inhibits hepatic fibrosis and injury in CCL4-induced hepatic fibrosis mice. (A) Images of livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB(40 mg/kg) and WeD(20 mg/kg). Representative micrographs of liver H&E staining, Sirius red, Masson and α-SMA staining were shown. Scale bars represent 50 μm. (B–D) Quantitative results of Sirius red(B), Masson(C) and α-SMA(D) staining sections. (E) Serum level of hydroxyproline of control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. (F) Quantitative PCR analysis of mRNA levels of α-SMA in livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. (G) Western blot analysis of Collagen1, p-Smad3, Smad2/3, p-IκBα, IκBα and GAPDH in livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. Data are expressed as Mean ± SD (n = 8 or 3 mice). Statistics differences were analyzed using One-way ANOVA followed by Tukey’s post hoc tes: *p < 0.05, **p < 0.01, ***p < 0.001. NS, no significance.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
schisandrol B, wedelolactone, hepatic fibrosis, combined pharmacotherapy, TGF-β1/Smads signaling pathway
Citation
Ai Y, Shi W, Zuo X, Sun X, Chen Y, Wang Z, Li R, Song X, Dai W, Mu W, Ding K, Li Z, Li Q, Xiao X, Zhan X and Bai Z (2021) Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice. Front. Pharmacol. 12:777914. doi: 10.3389/fphar.2021.777914
Received
16 September 2021
Accepted
21 September 2021
Published
07 October 2021
Volume
12 - 2021
Edited and reviewed by
Salvatore Salomone, University of Catania, Italy
Updates
Copyright
© 2021 Ai, Shi, Zuo, Sun, Chen, Wang, Li, Song, Dai, Mu, Ding, Li, Li, Xiao, Zhan and Bai.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhaofang Bai, baizf2008@hotmail.com; Xiaoyan Zhan, xyzhan123@163.com; Xiaohe Xiao, pharmacy_302@126.com
†These authors have contributed equally to this work
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.